Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
28 juin 2018 06h30 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience...
Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®
25 juin 2018 12h05 HE
|
Dynavax Technologies Corporation
In a Post-Hoc Analysis of Elderly Diabetic Patients, HEPLISAV-B was Well-Tolerated and Induced Higher Rates of Seroprotection than Engerix-B Data Presented at 2018 American Diabetes Association...
Dynavax to Present at the William Blair 38th Annual Growth Stock Conference
11 juin 2018 06h30 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Michael Ostrach, Dynavax’s Chief Financial Officer, will present at the...
Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
04 juin 2018 14h15 HE
|
Dynavax Technologies Corporation
Overall Response Rate (ORR) of 70% and 6-month Progression Free Survival (PFS) rate of 76% in Patients Naïve to Anti-PD-1 Treatment who Received the ≤ 2mg Dose of SD-101 Combination showed...
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
16 mai 2018 17h15 HE
|
Dynavax Technologies Corporation
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare...
Dynavax Reports First Quarter 2018 Financial Results
08 mai 2018 16h05 HE
|
Dynavax Technologies Corporation
Update on Initial Progress of HEPLISAV-B® Commercial Launch Conference Call to be Held at 4:30pm ET/1:30pm PT BERKELEY, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation...
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
07 mai 2018 06h30 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on May 1, 2018 the Compensation Committee of Dynavax’s Board of Directors (the...
Dynavax to Host First Quarter 2018 Financial Results Conference Call
02 mai 2018 16h15 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018...
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
23 avr. 2018 06h30 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention (CDC) published the Advisory...
Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
17 avr. 2018 09h07 HE
|
Dynavax Technologies Corporation
Demonstrates potential to achieve long-term, systemic responses Combination therapy was well tolerated Additional SD-101 data in head and neck squamous cell carcinoma presented at AACR BERKELEY,...